 Tonix Pharmaceuticals Holding Corp NASDAQ: TNXP received the official minutes from a Type B pre-Investigational New Drug Application IND meeting with the FDA. The meeting was related to TNX-102 SL1 cyclobenzaprine HCl sublingual tablets as a potential treatment for Long COVID Syndrome Long COVID, which is now known officially as Post-Acute Sequelae of COVID-19 PASC2. 